• The Journal of the Korea Contents Association
• /
• v.21 no.8
• /
• pp.691-701
• /
• 2021

Purpose: The purpose of this study was to identify the level of health literacy (HL) and self-management adherence and to investigate the relationship between HL and self-management adherence in patients with chronic obstructive pulmonary disease (COPD). Methods: The participants of this study were 165 patients with COPD from a tertiary general hospital located in G city from February 10th to May 10th, 2021. The general HL was measured by the Korean health literacy assessment tool (KHLAT), COPD specific HL was measured by COPD-related HL tool, and COPD self-management adherence was measured by the COPD self-management tool. Results: The mean score of general HL was 60.45±9.42. The mean score of the COPD-related HL was 47.03±8.82. The mean score of the COPD self-management adherence was 87.58±14.47. There were significant differences in the level of COPD-related HL according to age (t=2.43, p=.016), and in the level of general HL (F=10.96, p<.001) and the level of COPD-related HL according to the level of education (F=19.14, p<.001). There were significant correlations between the level of general HL and the level of COPD-related HL (r=.75, p<.001) and the level of COPD-related HL and the level of self-management adherence (r=.219, p=.005). Conclusion: The HL of COPD patients was at the level of mild school 1-2 years in this study. Therefore, nurses who care for COPD patients should understand patients' level of HL and communicate self-management skills with patients at a level appropriate for patients' HL. In addition, it is necessary to develop strategies to easily learn COPD-related information when providing self management skills or training.

• Annual Conference on Human and Language Technology
• /
• 2017.10a
• /
• pp.251-254
• /
• 2017

본 연구에서는 COPD와 기존에 연관이 있는 것으로 알려진 바이오마커 이외의 새로운 바이오마커를 찾고자 한다. Pubmed Data에서 선정한 암 관련 바이오마커를 추출하여 COPD와 암 관련 바이오마커의 관계를 파악하는 데이터로 사용한다. 그리고 워드 임베딩 모델 중 Word2vec을 사용하여 워드 임베딩 한다. 워드 임베딩한 K차원의 COPD와 암 관련 바이오마커를 t-SNE를 사용하여 시각화한다. 또한 코사인 유사도를 이용하여 COPD와 암 관련 바이오마커의 유사도를 측정한다. 그리고 코사인 유사도와 t-SNE 결과를 이용하여 COPD와 암 관련 바이오마커와의 상관관계를 파악할 수 있으며, 암 관련 바이오마커와 COPD 관련 바이오마커를 비교 하여 기존의 COPD와 연관이 있다고 알려진 바이오마커 이외의 새로운 바이오마커를 찾을 수 있다.

• 한국어정보학회:학술대회논문집
• /
• 2017.10a
• /
• pp.251-254
• /
• 2017

본 연구에서는 COPD와 기존에 연관이 있는 것으로 알려진 바이오마커 이외의 새로운 바이오마커를 찾고자 한다. Pubmed Data에서 선정한 암 관련 바이오마커를 추출하여 COPD와 암 관련 바이오마커의 관계를 파악하는 데이터로 사용한다. 그리고 워드 임베딩 모델 중 Word2vec을 사용하여 워드 임베딩 한다. 워드 임베딩한 K차원의 COPD와 암 관련 바이오마커를 t-SNE를 사용하여 시각화한다. 또한 코사인 유사도를 이용하여 COPD와 암 관련 바이오마커의 유사도를 측정한다. 그리고 코사인 유사도와 t-SNE 결과를 이용하여 COPD와 암 관련 바이오마커와의 상관관계를 파악할 수 있으며, 암 관련 바이오마커와 COPD 관련 바이오마커를 비교 하여 기존의 COPD와 연관이 있다고 알려진 바이오마커 이외의 새로운 바이오마커를 찾을 수 있다.

• Tuberculosis and Respiratory Diseases
• /
• v.85 no.4
• /
• pp.302-312
• /
• 2022

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease. Not all patients with COPD respond to available drugs. Identifying respondents to therapy is critical to delivering the most appropriate treatment and avoiding unnecessary medication. Recognition of individual patients' dominant characteristics by phenotype is a useful tool to better understand their disease and tailor treatment accordingly. To look for a suitable phenotype, it is important to understand what makes COPD complex and heterogeneous. The pathology of COPD includes small airway disease and/or emphysema. Thus, COPD is not a single disease entity. In addition, there are two types (panlobular and centrilobular) of emphysema in COPD. The coexistence of different pathological subtypes could be the reason for the complexity and heterogeneity of COPD. Thus, it is necessary to look for the phenotype based on the difference in the underlying pathology. Review of the literature has shown that clinical manifestation and therapeutic response to pharmacological therapy are different depending on the presence of computed tomography-defined airway wall thickening in COPD patients. Defining the phenotype of COPD based on the underlying pathology is encouraging as most clinical manifestations can be distinguished by the presence of increased airway wall thickness. Pharmacological therapy has shown significant effect on COPD with airway wall thickening. However, it has limited use in COPD without an airway disease. The phenotype of COPD based on the underlying pathology can be a useful tool to better understand the disease and adjust treatment accordingly.

• Tuberculosis and Respiratory Diseases
• /
• v.84 no.1
• /
• pp.35-45
• /
• 2021

Globally, cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are the leading causes of the non-communicable disease burden. Overlapping symptoms such as breathing difficulty and fatigue, with a lack of awareness about COPD among physicians, are key reasons for under-diagnosis and resulting sub-optimal care relative to COPD. Much has been published in the past on the pathogenesis and implications of cardiovascular comorbidities in COPD. However, a comprehensive review of the prevalence and impact of COPD management in commonly encountered cardiac diseases is lacking. The purpose of this study was to summarize the current knowledge regarding the prevalence of COPD in heart failure, ischemic heart disease, and atrial fibrillation. We also discuss the real-life clinical presentation and practical implications of managing COPD in cardiac diseases. We searched PubMed, Scopus, EMBASE, and Google Scholar for studies published 1981-May 2020 reporting the prevalence of COPD in the three specified cardiac diseases. COPD has high prevalence in heart failure, atrial fibrillation, and ischemic heart disease. Despite this, COPD remains under-diagnosed and under-managed in the majority of patients with cardiac diseases. The clinical implications of the diagnosis of COPD in cardiac disease includes the recognition of hyperinflation (a treatable trait), implementation of acute exacerbations of COPD (AECOPD) prevention strategies, and reducing the risk of overuse of diuretics. The pharmacological agents for the management of COPD have shown a beneficial effect on cardiac functions and mortality. The appropriate management of COPD improves the cardiovascular outcomes by reducing hyperinflation and preventing AECOPD, thus reducing the risk of mortality, improving exercise tolerance, and quality of life.

• Tuberculosis and Respiratory Diseases
• /
• v.66 no.3
• /
• pp.186-191
• /
• 2009

Background: Osteoporosis is a significant comorbidity in patients with chronic obstructive pulmonary disease (COPD). This study examined the prevalence and risk factors associated with osteoporosis in patients with COPD. Methods: The bone mineral densities (BMDs) of the lumbar spine and femoral bone were measured in 53 patients with clinically stable COPD and 41 age- and gender-matched control subjects showing a normal lung function. Osteoporosis was defined as a T-score $\leq$-2.5. The subjects' clinical characteristics and laboratory data were reviewed, and multiple logistic regression analysis was used to identify the risk factors associated with osteoporosis in COPD patients. Results: The prevalence of osteoporosis was 47% and 32% in the COPD patients and controls, respectively. In particular, using the femoral neck T-score, the prevalence of osteoporosis in COPD patients was higher than that in the controls (26% vs. 5%; p=0.006). The average T-score of the lumbar spine (p=0.025) and femoral neck of COPD patients were significantly lower than those of the controls (p=0.001). The forced expiratory volume in the 1 second ($FEV_1$) % predicted (p=0.019; odds ratio [OR], 0.955; 95% confidence interval [CI], 0.919-0.993) and age (p=0.024; OR, 1.144; 95% CI, 1.018-1.287) were independently associated with osteoporosis in patients with COPD. Conclusion: Using the femoral neck T-score, the prevalence of osteoporosis in patients with COPD was higher than the age-and gender-matched controls. A lower $FEV_1$ and older age further increase the risk of osteoporosis in patients with COPD.

• 건강소식
• /
• v.28 no.9 s.310
• /
• pp.28-29
• /
• 2004

현재 흡연으로 인한 COPD(만성폐쇄성폐질환)의 국내 의료비 부담이 심각한 것으로 드러났다. COPD 의료비 증가로 인한 경제적 부담감도 심각하지만, 천식 등으로 오인되는 COPD 환자 등 잠재환자의 증가와 더불어 COPD로 인한 사회경제적 손실도 더욱 커질 전망이다.

• Journal of Nutrition and Health
• /
• v.50 no.6
• /
• pp.585-594
• /
• 2017

Purpose: Food intake of COPD patients decreases because of appetite loss, depression, and breathing problems while eating, which increase the likelihood of patients becoming malnourished. This study investigated the nutrient intake and dietary quality of people with and without COPD in Korea. Methods: There were 2,160 adults aged 50 and over who participated in the $5{\sim}6^{th}$ Korea National Health and Nutrition Examination Survey. The subjects were divided into the COPD group and non-COPD group according to the rate of forced expiratory volume at 1 second (FEV1) against forced vital capacity (FVC). Consumption of food and nutrients were calculated based on the nutrition examination survey. Statistical analyses were conducted using SPSS 19.0. Results: Among individuals in their 50s, intake of vitamin $B_1$ in the COPD group was significantly less than the NCOPD group, while intake of sodium in the COPD group was significantly greater than the NCOPD group. Among individuals in their 60s, the energy intake of the COPD group was significantly less than that of the NCOPD group. The COPD group showed significantly less intake of vitamin $B_1$ and vitamin C, but greater intake of sodium than the NCOPD group. In the group aged 70 and over, The COPD group had significantly less intake of vitamin $B_1$ than the NCOPD group and showed lower nutrient adequacy ratio values in protein, vitamin $B_1$, vitamin $B_2$, and iron than the NCOPD group. Conclusion: The COPD group consumed less energy and certain nutrients, and their dietary quality was poor compared to the NCOPD group. Thus, more detailed research is required to understand the concrete relationship between COPD and malnutrition.

• Tuberculosis and Respiratory Diseases
• /
• v.80 no.3
• /
• pp.226-229
• /
• 2017

Chronic obstructive pulmonary disease (COPD) had been considered the only major disease that is continuing to increase in prevalence. There were a few studies about the change of the prevalence of COPD, which showed the prevalence of COPD did not increase. In this review, we report on the trends in the prevalence of COPD in Korea using the data from Korea National Health and Nutrition Examination Survey (KNHANES). The prevalence of COPD in 2015 was 13.4% (male, 21.6%; female, 5.8%). The prevalence of COPD did not change much, which ranged from 13.1% to 14.6% during the period from 2010 to 2015. Among the subjects found to have COPD by spirometry, only 2.8% had been diagnosed as COPD by physicians during the period from 2011 and 2015. In conclusion, the prevalence of COPD did not change significantly during the period from 2010 to 2015. And most COPD patients still had not been diagnosed by physicians and consequently had not been treated appropriately.

• Experimental and Molecular Medicine
• /
• v.50 no.11
• /
• pp.9.1-9.10
• /
• 2018

Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated in previous studies, knowledge of its role in COPD remains limited. The mechanism of FGF2 in a COPD mouse model and the therapeutic potential of rFGF-2 were investigated in COPD. The mechanism and protective effects of rFGF-2 were evaluated in cigarette smoke-exposed or elastase-induced COPD animal models. Inflammation was assessed in alveolar cells and lung tissues from mice. FGF-2 was decreased in the lungs of cigarette smoke-exposed mice. Intranasal use of rFGF-2 significantly reduced macrophage-dominant inflammation and alveolar destruction in the lungs. In the elastase-induced emphysema model, rFGF-2 improved regeneration of the lungs. In humans, plasma FGF-2 was decreased significantly in COPD compared with normal subjects (10 subjects, P = 0.037). The safety and efficacy of inhaled rFGF-2 use was examined in COPD patients, along with changes in respiratory symptoms and pulmonary function. A 2-week treatment with inhaled rFGF-2 in COPD (n = 6) resulted in significantly improved respiratory symptoms compared with baseline levels (P < 0.05); however, the results were not significant compared with the placebo. The pulmonary function test results of COPD improved numerically compared with those in the placebo, but the difference was not statistically significant. No serious adverse events occurred during treatment with inhaled rFGF-2. The loss of FGF-2 production is an important mechanism in the development of COPD. Inhaling rFGF-2 may be a new therapeutic option for patients with COPD because rFGF-2 decreases inflammation in lungs exposed to cigarette smoke.